Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Photoluminescence: Applications01:14

Photoluminescence: Applications

410
Photoluminescence offers a wide range of applications due to its inherent sensitivity and selectivity. This technique allows for both direct and indirect analyses of the analyte. Direct quantitative analysis is possible when the analyte exhibits a favorable quantum yield for fluorescence or phosphorescence. However, an indirect analysis may be feasible if the analyte is not fluorescent or phosphorescent, or if the quantum yield is unfavorable. Indirect methods include reacting the analyte with...
410
Photoluminescence: Fluorescence and Phosphorescence01:23

Photoluminescence: Fluorescence and Phosphorescence

2.1K
Photoluminescence is a process where a molecule absorbs light energy and re-emits it in the form of light. This phenomenon occurs when a substance absorbs photons, promoting its electrons to higher energy level excited states, followed by a relaxation process in which the electrons return to their original ground state energy levels and emit light. Photoluminescence is widely observed in various materials, including semiconductors, and organic and inorganic compounds.
A pair of electrons in a...
2.1K
Blinding01:11

Blinding

2.5K
Blinding is a commonly used method of not telling participants which treatment a subject is receiving. Blinding is a critical part of a randomized control trial or RCT. It reduces the bias that affects the results. In an RCT, blinding is used in the form of a placebo. A placebo effect occurs when untreated subjects falsely believe they have received the treatment and report improved symptoms. A placebo or a dummy treatment is administered to subjects to negate the bias caused by such an effect.
2.5K
Variables Affecting Phosphorescence and Fluorescence01:26

Variables Affecting Phosphorescence and Fluorescence

509
Fluorescence and phosphorescence are essential phenomena in fields like analytical chemistry, biological imaging, and materials science, where they detect molecular properties and visualize cellular structures. Understanding the variables that influence these luminescent behaviors is crucial for maximizing accuracy and efficiency in their applications. These variables can broadly be grouped into chemical structure, solvent properties, and external conditions, each playing a distinct role in...
509
Pigmentation01:19

Pigmentation

2.5K
The color of the skin is influenced by a number of pigments, including melanin, carotene, and hemoglobin. Recall that melanin is produced by cells called melanocytes, which are found scattered throughout the stratum basale of the epidermis. The melanin is transferred to the keratinocytes via melanosomes.
Melanin occurs in two primary forms: eumelanin that provides black and brown pigment and pheomelanin that provides red color. Dark-skinned individuals produce more melanin than those with pale...
2.5K
Focusing of Light in the Eye01:16

Focusing of Light in the Eye

2.9K
Light rays enter the eye through the cornea, a transparent dome-shaped tissue that is the eye's outermost layer. The cornea bends or refracts, light rays traveling to the pupil. The shape of the cornea determines how much of the light is bent and whether the image will be focused correctly on the retina at the back of the eye. Once the light has passed through both refraction layers, it converges into a single focal point onto a small area. This is where photoreceptors start transforming...
2.9K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Pain prevalence and intensity in advanced pancreatic cancer: a nationwide cohort study.

Pain·2026
Same author

Serum levels of the C-terminal pro-peptide of type V collagen have prognostic potential and are associated with a normal subtype of desmoplasia in a retrospective cohort of patients with esophagogastric cancer.

Therapeutic advances in medical oncology·2026
Same author

Antiphospholipid antibody formation during immune checkpoint inhibition in patients with cancer: a prospective cohort study.

Research and practice in thrombosis and haemostasis·2026
Same author

Circulating tumour DNA in oligometastatic oesophago-gastric cancers: applications, challenges, and future directions.

Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus·2026
Same author

Second-line oxaliplatin reintroduction or paclitaxel-ramucirumab in metastatic gastroesophageal cancer: a population-based study.

Therapeutic advances in medical oncology·2026
Same author

Imaging strategies for follow-up during adjuvant nivolumab in esophageal cancer: A multicenter retrospective cohort study.

PloS one·2026
Same journal

Transplantation tolerance versus immune evasion: Mechanistic divergences and therapeutic frontiers for islet cell replacement.

Cell reports. Medicine·2026
Same journal

Differential T cell clonal dynamics underlie outcomes to frontline chemoimmunotherapy in advanced gastric cancer.

Cell reports. Medicine·2026
Same journal

Targeted DNA triplex-forming oligonucleotide liposome for pulmonary fibrosis gene therapy.

Cell reports. Medicine·2026
Same journal

Metabolomic and lifestyle profiles refine BMI-metabolic phenotypes in older adults.

Cell reports. Medicine·2026
Same journal

Targeting cytokine-like protein FAM3D alleviates atherosclerosis.

Cell reports. Medicine·2026
Same journal

High-dose furmonertinib as first-line treatment for untreated EGFR-mutated advanced NSCLC with central nervous system metastases: A phase 2 trial.

Cell reports. Medicine·2026
查看所有相关文章

相关实验视频

Updated: Jul 13, 2025

Author Spotlight: Advancing Optogenetics Research Using Lustro
03:26

Author Spotlight: Advancing Optogenetics Research Using Lustro

Published on: August 4, 2023

728

在手套上的SPOTlight.

Sarah Derks1, Hanneke W M van Laarhoven2

  • 1Amsterdam UMC location Free University, Medical Oncology, De Boelelaan 1118, Amsterdam, the Netherlands; Cancer Center Amsterdam, Cancer Treatment and Quality of Life, Amsterdam, the Netherlands; Oncode Institute, Utrecht, the Netherlands.

Cell reports. Medicine
|October 18, 2023
PubMed
概括
此摘要是机器生成的。

索尔贝图西马布加化疗显著改善了克劳丁-18.2阳性胃癌患者的治疗结果. 这种一线治疗与单独安慰剂和化疗相比,显示出更高的疗效.

更多相关视频

Bioluminescent Optogenetics 2.0: Harnessing Bioluminescence to Activate Photosensory Proteins In Vitro and In Vivo
07:19

Bioluminescent Optogenetics 2.0: Harnessing Bioluminescence to Activate Photosensory Proteins In Vitro and In Vivo

Published on: August 4, 2021

4.7K
A Step Beyond BRET: Fluorescence by Unbound Excitation from Luminescence FUEL
07:04

A Step Beyond BRET: Fluorescence by Unbound Excitation from Luminescence FUEL

Published on: May 23, 2014

11.7K

相关实验视频

Last Updated: Jul 13, 2025

Author Spotlight: Advancing Optogenetics Research Using Lustro
03:26

Author Spotlight: Advancing Optogenetics Research Using Lustro

Published on: August 4, 2023

728
Bioluminescent Optogenetics 2.0: Harnessing Bioluminescence to Activate Photosensory Proteins In Vitro and In Vivo
07:19

Bioluminescent Optogenetics 2.0: Harnessing Bioluminescence to Activate Photosensory Proteins In Vitro and In Vivo

Published on: August 4, 2021

4.7K
A Step Beyond BRET: Fluorescence by Unbound Excitation from Luminescence FUEL
07:04

A Step Beyond BRET: Fluorescence by Unbound Excitation from Luminescence FUEL

Published on: May 23, 2014

11.7K

科学领域:

  • 在瘤学瘤学.
  • 胃肠病学 胃肠病学
  • 免疫治疗是一种免疫疗法.

背景情况:

  • 胃和胃食道结合腺癌是一个重大的全球健康挑战.
  • 克劳丁-18.2 (CLDN18.2) 是胃癌治疗中的新兴标.
  • 对于CLDN18.2-阳性患者,有效的第一线治疗选择有限.

研究的目的:

  • 为了评估Zolbetuximab与化疗结合的疗效和安全性,作为CLDN18.2-阳性,HER2-阴性胃或胃食道结合腺癌的第一线治疗.
  • 为了比较Zolbetuximab加化疗与安慰剂加化疗的结果.

主要方法:

  • GLOW试验是一项随机,双盲,安慰剂控制的第三期研究.
  • 患者接受了Zolbetuximab或安慰剂,并与capecitabine和oxaliplatin联合使用.
  • 评估了瘤CLDN18.2表达和HER2状态.

主要成果:

  • 与安慰剂和化疗相比,与capecitabine和oxaliplatin结合的zolbetuximab显示出了统计学上显著的改善.
  • 治疗方案一般耐受良好,副作用可控.
  • 特定的疗效终点,如无进展生存率和整体生存率,显示了益处.

结论:

  • 索尔贝图西马布加上卡佩西塔和氧沙是一种有效的第一线治疗选择,用于患有CLDN18.2-阳性,HER2-阴性胃或胃食道结合腺癌的患者.
  • 用佐尔贝图西马布准CLDN18.2代表了胃癌治疗的有前途的进展.
  • GLOW试验提供了高水平的证据,支持在这个患者群体中使用佐尔贝图西马布.